Sclerostin distribution in children and adolescents with type 1 diabetes mellitus and correlation with bone metabolism and bone mineral density
- PMID: 26094958
- DOI: 10.1111/pedi.12288
Sclerostin distribution in children and adolescents with type 1 diabetes mellitus and correlation with bone metabolism and bone mineral density
Abstract
Background and objective: Sclerostin is an inhibitor of the Wnt/beta-catenin bone metabolic pathway. Increased sclerostin levels and reduced bone mineral density (BMD) have been documented in adult patients with diabetes mellitus (DM), predominantly in those with type 2 diabetes mellitus (T2DM). No relative data exist on childhood type 1 diabetes mellitus (T1DM). Our objective was to study plasma sclerostin in T1DM children and adolescents and controls and its correlations with metabolic bone markers and BMD.
Subjects and methods: This was a cross-sectional study that was conducted at an outpatient clinical center. Forty T1DM children and adolescents were evaluated (mean ± SD age: 13.04 ± 3.53 yr, T1DM duration: 5.15 ± 3.33 yr), along with 40 healthy matched controls (age 12.99 ± 3.3 yr). Sclerostin, soluble receptor activator of nuclear factor-kappaB ligand (s-RANKL), osteoprotegerin, osteocalcin, C-telopeptide crosslinks, electrolytes, parathyroid hormone (PTH), and total 25(OH)D were measured. Lumbar and subcranial total body BMD were evaluated with dual energy X-ray absorptiometry (DXA).
Results: Sclerostin levels demonstrated a Gaussian distribution, with no significant difference between patients and controls (51.56 ± 12.05 vs. 50.98 ± 13.55 pmol/L, p = 0.84). Significantly lower values were found in girls and prepubertal children. Sclerostin values were significantly and gradually increased in children through pubertal Tanner stages 1-3, were reduced at stage 4 and increased again at pubertal stage 5. Sclerostin levels were positively correlated with logCTX (logarithm of C-terminal telopeptide crosslinks of type I collagen), logOsteocalcin (logarithm of Osteocalcin), magnesium, total body, and L1-L4 BMD z-score.
Conclusions: T1DM patients had similar levels of sclerostin with controls. Sclerostin correlated with bone resorption and formation markers and also with bone mass indices, gender, and pubertal stage. The decrease in sclerostin values observed in pubertal stage 4 adolescents coincides with the concurrent growth spurt, and is consistent with sclerostin physiology as an inhibiting signal.
Keywords: adolescents; bone metabolism; children; osteopenia; sclerostin; type 1 diabetes.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
-
Skeletal growth and bone mineral acquisition in type 1 diabetic children; abnormalities of the GH/IGF-1 axis.Growth Horm IGF Res. 2017 Jun;34:13-21. doi: 10.1016/j.ghir.2017.04.003. Epub 2017 Apr 28. Growth Horm IGF Res. 2017. PMID: 28482269 Free PMC article. Review.
-
MECHANISMS IN ENDOCRINOLOGY: Diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis.Eur J Endocrinol. 2017 Mar;176(3):R137-R157. doi: 10.1530/EJE-16-0652. Eur J Endocrinol. 2017. PMID: 28049653 Review.
-
Increased levels of Dickkopf-1 are indicative of Wnt/β-catenin downregulation and lower osteoblast signaling in children and adolescents with type 1 diabetes mellitus, contributing to lower bone mineral density.Osteoporos Int. 2017 Mar;28(3):945-953. doi: 10.1007/s00198-016-3802-5. Epub 2016 Oct 20. Osteoporos Int. 2017. PMID: 27766367
-
Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.Osteoporos Int. 2016 Apr;27(4):1631-1643. doi: 10.1007/s00198-015-3422-5. Epub 2015 Nov 20. Osteoporos Int. 2016. PMID: 26588909
-
Clinical and endocrine correlates of circulating sclerostin levels in patients with type 1 diabetes mellitus.Clin Endocrinol (Oxf). 2014 May;80(5):649-55. doi: 10.1111/cen.12364. Epub 2013 Dec 12. Clin Endocrinol (Oxf). 2014. PMID: 24237244
Cited by
-
Pediatric Type 1 Diabetes: Mechanisms and Impact of Technologies on Comorbidities and Life Expectancy.Int J Mol Sci. 2023 Jul 26;24(15):11980. doi: 10.3390/ijms241511980. Int J Mol Sci. 2023. PMID: 37569354 Free PMC article. Review.
-
The role of wnt signaling in diabetes-induced osteoporosis.Diabetol Metab Syndr. 2023 Apr 28;15(1):84. doi: 10.1186/s13098-023-01067-0. Diabetol Metab Syndr. 2023. PMID: 37106471 Free PMC article. Review.
-
Relationship Between Sclerostin (SOST) Expression and Genetic Loci rs851056, rs1230399 Polymorphisms and Bone Mineral Density in Postmenopausal Women with Type 2 Diabetes in Xinjiang.Diabetes Metab Syndr Obes. 2021 Nov 4;14:4443-4450. doi: 10.2147/DMSO.S305831. eCollection 2021. Diabetes Metab Syndr Obes. 2021. PMID: 34764662 Free PMC article.
-
Mechanisms of altered bone remodeling in children with type 1 diabetes.World J Diabetes. 2021 Jul 15;12(7):997-1009. doi: 10.4239/wjd.v12.i7.997. World J Diabetes. 2021. PMID: 34326950 Free PMC article. Review.
-
Bone Mineral Density and Type 1 Diabetes in Children and Adolescents: A Meta-analysis.Diabetes Care. 2021 Aug;44(8):1898-1905. doi: 10.2337/dc20-3128. Epub 2021 Jul 20. Diabetes Care. 2021. PMID: 34285100 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical